Grace Therapeutics holder buys 15K shares

Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P.

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) reported that Opaleye Management Inc., a ten percent owner, indirectly purchased additional common stock through Opaleye, L.P. The fund bought 9,393 shares on September 8, 2026 at a weighted average price of $2.0972 per share and 5,836 shares on September 9, 2026 at a weighted average price of $2.0899 per share in open-market or private transactions. The prices reflect ranges of $2.095–$2.10 and $2.085–$2.09, respectively, and Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest; no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Buyer: 15,229 shares

Net Buy 2 txns

Insider Opaleye Management Inc.

Role 10% Owner

Bought 15,229 shs ($32K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share F3, F1, F4	5,836	$2.0899	$12K
Purchase	Common Stock, par value $0.0001 per share F2, F1, F4	9,393	$2.0972	$20K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 2,775,229 shares (Indirect, By Opaleye, L.P.)

Footnotes (4)

1. F1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
2. F2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.095 to $2.10. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
3. F3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.085 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
4. F4. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Key Figures

Shares purchased September 8, 2026: 9,393 shares Weighted average price September 8, 2026: $2.0972 per share Price range September 8, 2026: $2.095–$2.10 per share +5 more

8 metrics

Shares purchased September 8, 2026 9,393 shares Indirect purchase of GRCE common stock by Opaleye, L.P.

Weighted average price September 8, 2026 $2.0972 per share GRCE shares bought in multiple transactions within a $2.095–$2.10 range

Price range September 8, 2026 $2.095–$2.10 per share Range of prices for GRCE shares underlying the weighted average

Shares purchased September 9, 2026 5,836 shares Indirect purchase of GRCE common stock by Opaleye, L.P.

Weighted average price September 9, 2026 $2.0899 per share GRCE shares bought in multiple transactions within a $2.085–$2.09 range

Price range September 9, 2026 $2.085–$2.09 per share Range of prices for GRCE shares underlying the weighted average

Total shares purchased 15,229 shares Aggregate GRCE shares acquired across both reported transactions

Ownership status Ten percent owner Reporting person status of Opaleye Management Inc. in relation to GRCE

Key Terms

weighted average price, beneficially own, pecuniary interest, ten percent owner

4 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficially own regulatory

"may be deemed to beneficially own the securities owned directly"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

pecuniary interest financial

"disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest"

ten percent owner regulatory

"reporting person is marked as a ten percent owner"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GRCE report in this Form 4?

Grace Therapeutics reported that Opaleye Management Inc., a ten percent owner, indirectly purchased a total of 15,229 common shares through Opaleye, L.P. in two open-market or private transactions in September 2026.

On what dates did the GRCE insider purchases by Opaleye occur?

The purchases were made on September 8, 2026 and September 9, 2026. On September 8, 9,393 GRCE shares were acquired, and on September 9, 5,836 GRCE shares were acquired, all indirectly through Opaleye, L.P.

At what prices were the GRCE shares acquired in this Form 4 filing?

The reported prices are weighted averages. On September 8, 2026, GRCE shares were bought at a weighted average of $2.0972 within a $2.095–$2.10 range. On September 9, 2026, shares were bought at a weighted average of $2.0899 within a $2.085–$2.09 range.

Were the GRCE insider purchases made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating that these GRCE transactions were executed under a Rule 10b5-1 or similar pre-arranged trading plan.

Who is the reporting person in the GRCE Form 4 and how are the shares held?

The reporting person is Opaleye Management Inc., a ten percent owner of GRCE. The shares are held indirectly, owned directly by Opaleye, L.P., and Opaleye Management Inc. may be deemed to beneficially own them as the fund’s investment manager, subject to a pecuniary-interest limitation.

Does Opaleye Management Inc. claim full beneficial ownership of the GRCE shares?

No. Opaleye Management Inc. explicitly disclaims beneficial ownership of the reported GRCE shares except to the extent of its pecuniary interest, stating that the Form 4 should not be construed as an admission of beneficial ownership for Section 16(a) or any other purpose.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:06 PM Accepted by SEC EDGAR 09/10/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Opaleye Management Inc.

(Last) (First) (Middle)

ONE BOSTON PLACE, 26TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	09/08/2026		P		9,393	A	$2.0972(2)	2,769,393	I	By Opaleye, L.P.(1)(4)
Common Stock, par value $0.0001 per share	09/09/2026		P		5,836	A	$2.0899(3)	2,775,229	I	By Opaleye, L.P.(1)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.

2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.095 to $2.10. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.085 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

4. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

	Opaleye Management, Inc., By: /s/ James Silverman, President	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)